FY2025 · ended Dec 31, 2025 · Revenue $85.33M, -6.2% YoY · Filed Mar 16, 2026
Standard Biotools Inc. (LAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $85.3 million and a net loss of $74.9 million. Free cash flow was -$82.6 million. As of Sep 30, 2026 it held $559.4 million in cash and investments and $26.5 million in total debt.
Revenue (TTM)
$84.43M
-2.2% vs year-ago TTM
Net income (TTM)
$133.08M
+203.8% vs year-ago TTM
Operating cash flow (TTM)
$-64.26M
+26.3% vs year-ago TTM
Free cash flow (TTM)
$-65.65M
+33.3% vs year-ago TTM
EPS (TTM)
$0.34
+201.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
390.07M
+2.9% vs prior year
Net cash
$532.82M
as of Sep 30, 2026
Operating margin
-97.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1162194
- Former names
- FLUIDIGM CORP (until Apr 1, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M |
| Operating income | -$110.2M | -$127.5M | -$76.6M | -$116.2M | -$67.5M |
| Net income | -$74.9M | -$138.9M | -$74.7M | -$190.1M | -$59.2M |
| Diluted EPS | -$0.20 | -$0.52 | -$0.94 | -$2.43 | -$0.78 |
| Operating cash flow | -$74.3M | -$143.5M | -$43.3M | -$89.4M | -$44.1M |
| Free cash flow | -$82.6M | -$151.8M | -$46.1M | -$93.2M | -$57.3M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M | $180.6M |
| Stockholders' equity | $424.3M | $471.7M | -$148.1M | -$81.5M | $94.6M |
| Cash and investments | $213.3M | $292.9M | $114.9M | $165.8M | $28.5M |
| Total debt | $30.5M | $33.0M | $98.2M | $37.8M | $40.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
All 1000 Standard Biotools Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.